Skip to main content
An official website of the United States government
Email

ImmunoOncology Branch (IOB)

ImmunoOncology Branch (IOB)

IOB manages the grants portfolio within DTP on preclinical cancer immunotherapy and strategies to manage their resistance and toxicity. In general, cancer immunotherapy implies use of the immune system to treat cancer. Immunotherapy can be used alone or in combination with other therapies. Studies can use preclinical models such as tumor-bearing animals to evaluate safety and therapeutic efficacy of an agent (s) or include analysis of human patient specimens. Applications which propose conducting human clinical trials belong in CTEP’s portfolio within DCTD. The IOB grant portfolio includes, but is not limited to, studies on:

  • Immune checkpoint Inhibitor (ICI) therapies – “classic” T cell checkpoint therapies such as anti-PD1 and anti-CTLA4 blockade, additional checkpoints for T cells and checkpoints for immune cells other than T cells, resistance to ICI therapies, immune-related adverse events resulting from checkpoint inhibitor therapies
  • Adoptive immune cell therapies – CAR T cell therapies, adoptive immune cell therapies using immune cells other than T cells, modifying the tumor microenvironment and other strategies to improve adoptive immune cell therapy efficacy
  • In vivo immune cell therapies – viral or non-viral based in vivo delivery of genetic material to modify and reprogram immune cells for cancer therapy
  • Therapies that modulate the immune system via cytokines, chemokines, oncoviruses, antibodies, cancer vaccines and other biologics - evaluation of immune modulating agents that impact immune cell function to improve therapeutic intent in animal models, in vitro systems, and as correlative biomarker studies.
  • Comparative oncology – with special interest in canine clinical trials using pet dogs with spontaneous tumors to inform treatment of human cancers
  • Microbiome and microbiome-based treatments in immunotherapy efficacy and toxicity
  • Pediatric Immunotherapy- develop novel and effective immunotherapies for children and adolescents with tumors.

Networks with IOB participation: 

Other programs with IOB participation:

If you would like to reproduce some or all of this content, see Reuse of NCI Information for guidance about copyright and permissions. In the case of permitted digital reproduction, please credit the National Cancer Institute as the source and link to the original NCI product using the original product's title; e.g., “ImmunoOncology Branch (IOB) was originally published by the National Cancer Institute.”

Email